Flow cytometric analysis of KLRG1 expression on C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes were stained with Alexa Fluor® 647 Mouse Anti-Mouse NK1.1 Antibody and either Alexa Fluor® 488 Armenian Hamster IgG Isotype Control (Left panel) or SDT Alexa Fluor® 488 Armenian Hamster Anti-Mouse/Human KLRG1 Antibody (Right panel) at 1.25μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Armenian hamster |
| Antigen | KLRG1 |
| Synonyms | Killer cell lectin-like receptor subfamily G member 1; C-type lectin domain family 15 member A; ITIM-containing receptor MAFA-L; MAFA-like receptor; Mast cell function-associated antigen; CLEC15A; MAFA; MAFAL |
| Location | Cell membrane |
| Accession | Q96E93、O88713 |
| Clone Number | S-R655 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | FCM |
| Reactivity | Hu, Ms |
| Positive Sample | C57BL/6 mouse splenocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 488 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu, Ms |
Background
Killer cell lectin-like receptor G1 (KLRG1) is a 30–35 kDa C-type lectin-like inhibitory receptor expressed predominantly on the surface of late-differentiated effector and effector-memory CD8⁺ T, NK, NKT and some CD4⁺ T cells, where its engagement by ubiquitous E-, N- or R-cadherins on epithelial or vascular structures delivers SHP-1/2-dependent signals that terminate calcium flux, cytotoxic granule release and proliferation, thereby acting as a crucial “brake” on acute and chronic immune responses; up-regulated by repeated antigen or IL-2/IL-15 stimulation, KLRG1 demarcates short-lived effector cells destined for apoptosis versus long-lived memory precursors, and its genetic or antibody blockade enhances viral clearance, tumor control and vaccine efficacy, while its sustained expression correlates with T-cell exhaustion, immunosenescence and impaired survival in infections, cancer and autoimmunity, positioning KLRG1 as a key biomarker and therapeutic target for immune rejuvenation.
Picture
Picture
FC
